Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei CNCM I-4034
- Development stage
- Unknown
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactobacillus paracasei CNCM I-4034** is a proprietary probiotic bacterial strain isolated from the feces of exclusively breast-fed newborn infants. It was selected for its probiotic properties, including the ability to adhere to intestinal mucus, resistance to biliary salts and low pH, and sensitivity to various antibiotics. In clinical and preclinical studies, this strain has demonstrated safety and good tolerance when administered to healthy volunteers and animal models. Its main mechanism of action is immunomodulation: intake is associated with increases in anti-inflammatory interleukins (such as IL-10 and IL-4), reduction in pro-inflammatory cytokines (notably IL-6), and an improved anti-inflammatory marker profile. Additionally, it has shown potential benefit in reducing liver steatosis and systemic inflammation in models of metabolic dysfunction. The strain is of interest for gut health, metabolic disorders, and immune modulation[1][2][3].
- Other names
- Lactobacillus paracasei CNCM I-4034
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on lactobacillus paracasei CNCM I-4034.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei CNCM I-4034.